Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Stock Price Today
Aura AI Summary
Key Stats
- $73.20BMarket Cap
- 2,903,974Volume
- -Sector
- $50.6352W High
- $49.1852W Low
- 91 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vanguard Sht-Term Inflation-Protected Sec Idx ETF has traded between a low of $49.18 and a high of $50.63, highlighting its annual price range. Buy and sell Vanguard Sht-Term Inflation-Protected Sec Idx ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Most Recent News
First Hydrogen completes unmanned ground vehicle, gains exclusive global patent rights.
First Hydrogen Corp. has successfully built its unmanned ground vehicle (UGV), achieving a key development milestone and securing exclusive worldwide rights to the related patented technology for the patent's remaining life, with a 1% royalty on sale...

Coiled Therapeutics expects first safety data for new AO-252 cancer drug formulation by end of 2026
Coiled Therapeutics plans to report initial safety and pharmacokinetic data for its new AO-252 cancer drug formulation by the end of 2026 after dosing up to 30 patients. The new lipid-based softgel aims to improve drug absorption and consistency, wit...

Poolbeg Pharma doses 8 patients in trial to prevent cancer immunotherapy side effect CRS
Poolbeg Pharma has dosed eight patients in its TOPICAL trial testing POLB 001 to prevent cytokine release syndrome (CRS), a dangerous immune reaction caused by cancer immunotherapy. The trial targets multiple myeloma patients receiving teclistamab, a...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.